Blood vessels, a potential therapeutic target in rheumatoid arthritis?

Joint Bone Spine

Volumn 78, Issue 2, 2011, Pages 118-123

  Semerano, Luca ^a,b   Clavel, Gaëlle ^b,c   Assier, Eric ^b   Denys, Anne ^b   Boissier, Marie Christophe ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

Angiogenesis; Atherosclerosis; Cardiovascular disease; Rheumatoid arthritis; Targeted treatments

Indexed keywords

BEVACIZUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETARACIZUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PIOGLITAZONE; RITUXIMAB; SORAFENIB; SUNITINIB; THROMBOSPONDIN 2; TOCILLIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; INFLAMMATION; KIDNEY CANCER; NONHUMAN; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SOLID TUMOR;

ANGIOGENESIS INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD VESSELS; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; SYNOVIAL MEMBRANE;

EID: 79952248595     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.06.004     Document Type: Short Survey

References (60)

1. Avouac J., Uzan G., Kahan A., et al. Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine 2008, 75:131-137.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
3. Gerhardt H., Semb H. Pericytes: gatekeepers in tumour cell metastasis?. J Mol Med 2008, 86:135-144.
4. Paleolog E.M. The vasculature in rheumatoid arthritis: cause or consequence?. Int J Exp Pathol 2009, 90:249-261.
5. Khong T.L., Larsen H., Raatz Y., et al. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 2007.
6. Lainer-Carr D., Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007, 3:434-442.
7. Rad F.H., Le Buanec H., Paturance S., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007, 104:2837-2842.
8. Tarallo V, Vesci L, Capasso O, et al. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 2010;70:1804-13.
9. Luttun A., Tjwa M., Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002, 979:80-93.
10. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
11. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999, 56:794-814.
12. Shim W.S., Ho I.A., Wong P.E. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007, 5:655-665.
13. Arsic N., Zentilin L., Zacchigna S., et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 2003, 7:450-459.
14. Eklund L., Olsen B.R. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006, 312:630-641.
15. Szekanecz Z., Besenyei T., Paragh G., et al. New insights in synovial angiogenesis. Joint Bone Spine 2010, 77:13-19.
16. Costa C., Incio J., Soares R. Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis 2007, 10:149-166.
17. Wilder R.L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002, 61(Suppl. 2):96-99. [ii].
18. Sivakumar B., Akhavani M.A., Winlove C.P., et al. Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg [Am] 2008, 33:49-58.
19. Hollander A.P., Corke K.P., Freemont A.J., et al. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544.
20. Giatromanolaki A., Sivridis E., Maltezos E., et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003, 5:R193-201.
21. Kennedy A., Ng C.T., Biniecka M., et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 2010, 62:711-721.
22. Clavel G., Valvason C., Yamaoka K., et al. Relationship between angiogenesis and inflammation in experimental arthritis. Eur Cytokine Netw 2006, 17:202-210.
23. Lu J., Kasama T., Kobayashi K., et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 2000, 164:5922-5927.
24. Sone H., Kawakami Y., Sakauchi M., et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001, 281:562-568.
25. Afuwape A.O., Feldmann M., Paleolog E.M. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 2003, 10:1950-1960.
26. De Bandt M., Ben Mahdi M.H., Ollivier V., et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 2003, 171:4853-4859.
27. Grosios K., Wood J., Esser R., et al. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 2004, 53:133-142.
28. Jin P., Zhang J., Sumariwalla P.F., et al. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res Ther 2008, 10:R73.
29. Chen Y., Donnelly E., Kobayashi H., et al. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005, 52:1585-1594.
30. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
31. Oliver S.J., Banquerigo M.L., Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994, 157:291-299.
32. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1alpha and cancer therapy. Recent Results Cancer Res 2010;180:15-34.
33. Kucharz E.J., Gozdzik J., Kopec M., et al. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:273-274.
34. Yue L., Shen Y.X., Feng L.J., et al. Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 2007, 567:166-170.
35. Kim J.M., Ho S.H., Park E.J., et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002, 46:793-801.
36. Sumariwalla P.F., Cao Y., Wu H.L., et al. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 2003, 5:R32-R39.
37. Trocme C., Marotte H., Baillet A., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333.
38. Erdem H., Pay S., Musabak U., et al. Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis?. Rheumatol Int 2007, 27:969-973.
39. Park Y.W., Kang Y.M., Butterfield J., et al. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 2004, 165:2087-2098.
40. Bongartz T., Coras B., Vogt T., et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 2005, 44:126-129.
41. Wilasrusmee C., Yusupov I., Ondocin P., et al. Angiocidal effect of cyclosporin A: a new therapeutic approach for pathogenic angiogenesis. Int Angiol 2005, 24:372-379.
42. Tomoda R., Seto M., Hioki Y., et al. Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clin Exp Metastasis 2005, 22:559-564.
43. Goedkoop A.Y., Kraan M.C., Picavet D.I., et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004, 6:R326-R334.
44. Markham T., Mullan R., Golden-Mason L., et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006, 54:1003-1012.
45. Campanati A., Goteri G., Simonetti O., et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2009, 22:371-377.
46. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
47. Paradis T.J., Floyd E., Burkwit J., et al. The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother 2001, 50:125-133.
48. Nakahara H., Song J., Sugimoto M., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
49. Shinriki S., Jono H., Ota K., et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009, 15:5426-5434.
50. del Rincon I.D., Williams K., Stern M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
51. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340:115-126.
52. Cardillo C., Schinzari F., Mores N., et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006, 80:275-281.
53. Gonzalez-Gay M.A., Garcia-Unzueta M.T., De Matias J.M., et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:373-379.
54. Maki-Petaja K.M., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006, 114:1185-1192.
55. Foster W., Shantsila E., Carruthers D., et al. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. Rheumatology (Oxford) 2009, 48:285-288.
56. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003, 9:1370-1376.
57. Grisar J., Aletaha D., Steiner C.W., et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 2007, 66:1284-1288.
58. Fadini G.P., Coracina A., Baesso I., et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 2006, 37:2277-2282.
59. Pakozdi A., Besenyei T., Paragh G., et al. Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. Joint Bone Spine 2009, 76:581-583.
60. van Zonneveld AJ, de Boer HC, van der Veer EP, et al. Inflammation, vascular injury and repair in rheumatoid arthritis. Ann Rheum Dis 2010;69(Suppl. 1):57-60 [i].